Dinesh Patel, Protagonist Therapeutics CEO
Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug
J&J and biotech partner Protagonist Therapeutics claimed a Phase IIb win in plaque psoriasis Tuesday morning. But near-term plans for the drug remain murky. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.